Clinical trials
Advanced Pancreatic Adenocarcinoma clinical trials
Below are recruiting advanced pancreatic adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 235 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07114861RecruitingPhase 1/Phase 2
KN510713 with mFOLFIRINOX for advanced pancreatic cancer
This study tests a new drug (KN510713) combined with the standard chemotherapy mFOLFIRINOX for people with advanced pancreatic cancer that hasn't had prior chemotherapy. The goal is to see if adding the new drug can improve outcomes.
Goyang-siAges 19–75 - NCT06458712RecruitingPhase 1
Testing a new drug for advanced cancers with gene changes
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
Sacramento, CaliforniaAges 18 years+ - NCT04361708RecruitingPhase 1
Test drug combo chemotherapy for advanced pancreas and upper GI cancers
This early-phase study tests how safe and workable it is to combine irinotecan with several standard chemotherapy medicines for cancers like pancreatic and other upper GI cancers. It’s mainly looking for side effects and the best way the doses work in people with advanced or metastatic disease.
Chicago, IllinoisAges 18 years+ - NCT06199895RecruitingPhase 2
Study of paclitaxel for patients with taxane-resistant solid tumors
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Wuhan, HubeiAges 18 years+ - NCT01365169Recruiting
How activity level and daily function relate to cancer survival
This study looks at how physical activity (movement during the day) and a clinician-rated “day-to-day function” score relate to overall survival in people with certain cancers. It may help doctors understand who benefits most from activity-focused care and better monitoring.
Houston, TexasAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT04622423Recruiting
Advanced therapies for colon or pancreas liver metastases
This study tests advanced treatments for cancer that has spread to the liver, either from colon cancer or pancreatic cancer. It may help by targeting liver tumors using treatment plans and, for some participants, liver tissue samples.
Milan, MilanAges 18 years+ - NCT07529808RecruitingPhase 1/Phase 2
New Drug BHB810 for Advanced Stomach Cancer
This trial tests a new drug called BHB810 for gastric (stomach) and gastroesophageal junction cancer that has stopped responding to standard treatments or has no standard options available. The drug targets a protein called CDH17 found on cancer cells and may help slow or shrink the tumor.
Duarte, CaliforniaAges 18 years+ - NCT04911816RecruitingPhase 1/Phase 2
Pre-surgery chemo plus oral hydroxychloroquine for pancreatic cancer
This trial studies giving chemo and hydroxychloroquine before surgery for resectable pancreatic cancer. The goal is to shrink the tumor and improve the chances of successful removal.
Morgantown, West VirginiaAges 18 years+ - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70 - NCT07670312RecruitingPhase 1/Phase 2
Testing XYA02 for advanced solid tumors
This study tests an experimental drug called XYA02 for people with advanced solid tumors (like lung, ovarian, stomach, colorectal, or pancreatic cancer) that have come back or not responded to other treatments. The goal is to see if XYA02 can shrink tumors or slow their growth, and to find the best dose.
Sydney, New South WalesAges 18 years+ - NCT05723107RecruitingPhase 1
Testing an endoscopic treatment for pancreatic cancer that can't be removed
This early-phase trial is testing a new endoscopic (from inside the stomach) approach for pancreatic ductal adenocarcinoma that is locally advanced and cannot be removed with surgery. It may help some people who have already tried first chemotherapy and still have a tumor confined to the pancreas area (no spread).
New York, New YorkAges 18 years+ - NCT06196788RecruitingPhase 2
Artery infusion chemo for advanced pancreatic cancer
This trial tests a treatment called transcatheter arterial infusion, where chemotherapy drugs are delivered directly to the tumor through a thin tube in an artery. It's for people with advanced pancreatic cancer who haven't had other treatments yet.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07683221RecruitingPhase 2
Combination treatment for locally advanced pancreatic cancer
This trial tests a new combination of drugs with radiation therapy for people with locally advanced pancreatic cancer that cannot be removed with surgery. The treatment aims to shrink the tumor and improve outcomes.
Jinan, ShandongAges 18–75 - NCT07600268RecruitingPhase 2
Radiation plus maintenance drugs for advanced pancreatic cancer
This trial tests whether adding a focused radiation treatment (SBRT) to ongoing chemotherapy drugs works better than the drugs alone for pancreatic cancer that has stabilized or shrunk after initial treatment. The goal is to see if this combination approach helps patients live longer.
Jinan, ShandongAges 18–70 - NCT05859750RecruitingPhase 2
AK104 plus chemotherapy for advanced pancreatic cancer
This trial tests AK104 (an antibody medicine) given with standard chemotherapy as the first treatment for advanced pancreatic ductal cancer. It aims to see whether this combination works better and is safe for people with cancer that has spread or is advanced.
Beijing, Beijing MunicipalityAges 18–75 - NCT07481383RecruitingPhase 1
Implant device for chemo delivery in advanced pancreatic cancer
This trial tests an implantable device that delivers chemotherapy (gemcitabine) directly to pancreatic tumors. It may offer a new treatment option for people with non-metastatic, advanced pancreatic cancer that cannot be surgically removed.
Ann Arbor, MichiganAges 18 years+ - NCT05827796RecruitingPhase 1/Phase 2
Testing IN10018 plus chemo with an added antibody in pancreatic cancer
This Phase 1/2 trial tests a new medicine (IN10018) and a specific added antibody (KN046) together with standard chemotherapy for advanced pancreatic cancer. It aims to see whether this combination can better control the cancer and how safely it can be given.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07114315RecruitingPhase 2
Study of AK130 plus AK112 for advanced pancreatic cancer
This trial tests a combination of two investigational drugs, AK130 and AK112, for people with advanced pancreatic cancer. It may be an option if you have had 1 or 2 prior treatments and are still relatively healthy.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06532617RecruitingPhase 2
New drug combo for advanced pancreatic cancer after first treatment
This trial tests a new drug combo (cadonilimab plus either S-1 or capecitabine) for people with advanced pancreatic cancer that has not spread to other organs and who have already tried one standard treatment. The goal is to see if this combination can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05132244Recruiting
Monitoring blood sugar levels in people starting pancreatic cancer treatment
This study looks at how well blood sugar (glucose) levels can be monitored and managed in people with pancreatic cancer who are starting their first treatment. It aims to understand if careful glucose management can improve well-being and possibly treatment outcomes.
Vancouver, British ColumbiaAges 18 years+ - NCT04999761RecruitingPhase 1
Study testing new drug combinations for advanced cancers
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
AichiAges 18 years+ - NCT07812805RecruitingPhase 1
New targeted treatment with imaging for advanced solid tumors
This trial tests a new experimental treatment (SKL35501) that uses a special imaging agent (SKL35502) to find and target a marker called NTSR1 found on some advanced cancers. The goal is to see if this treatment is safe and can help people whose cancer has stopped responding to standard treatments.
Glen Burnie, MarylandAges 18 years+ - NCT06576115RecruitingPhase 2
Combination therapy with device for metastatic pancreatic cancer
This trial tests whether adding a non-invasive device that uses low-level radio waves to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with pancreatic cancer that has spread to other parts of the body.
Clarkston, MichiganAges 18 years+
Hear when a new Advanced Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced pancreatic adenocarcinoma?
- Yes. Clin2 currently lists 235 recruiting advanced pancreatic adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced pancreatic adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced pancreatic adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Pancreatic Adenocarcinoma Advanced or Metastatic
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Adenocarcinoma
- Metastatic Pancreatic Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.